Stifel analyst Annabel Samimy raised the firm’s price target on Jazz Pharmaceuticals to $230 from $225 and keeps a Buy rating on the shares as the firm lays out initial expectations for Jazz’s zanidatamab in the three currently-studied indications of second-line BTC, first-line GEA and HER2+/HR+ locally-advanced breast cancer ahead of the company’s zanidatamab R&D Day.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JAZZ:
- Zymeworks price target raised to $14 from $12 at Wells Fargo
- Avadel Pharmaceuticals price target raised to $22 from $20 at Needham
- Avadel Pharmaceuticals price target raised to $22 from $20 at Craig-Hallum
- Avadel Pharmaceuticals price target raised to $29 from $27 at Oppenheimer
- Avadel Pharmaceuticals ‘pleased’ with ruling in patent litigation with Jazz Pharmaceuticals
